Navidea Biopharmaceuticals Inc (NAVB)

[sts66]

Ridiculous - supposed pro-NAVB "expert" says LS sales will be abysmal:

http://seekingalpha.com/article/1299321-these-4-biotech-stocks-have-upside-says-burrill-s-senior-analyst?source=yahoo


Dr. Benjamin: We project Lymphoseek to garner 46% of the intralymphatic mapping market worldwide by 2016. Using a price of $300 per procedure, we believe revenues in the U.S. could reach $61.5 MM. Now remember that these revenues are split with their North American partner Cardinal Health. Given the 50:50 revenue split, revenues to Navidea in the U.S. alone should be approximately $31 MM. Europe on the other hand is a whole other issue. The company recently filed a MAA and could receive approval by late 2013. Given a similar price point, we believe sales of Lymphoseek could reach $77 MM by 2016. These sales assumptions involve a European partner who could acquire rights to the drug by providing Navidea with a 35% royalty rate, in addition to an upfront payment and sales milestones. If Navidea is successful in securing a marketing partner in Europe (expected in 2Q13), we believe EU revenues to Navidea could reach $27 MM in 2016.

Those numbers are a far cry from the revs being written about on places like the IV NAVB board, and even in other SA articles - I've seen +$450M worldwide multiple times, this guy is saying 1/10th of that, and he LIKES NAVB and LS?!?! I think he's a wolf in sheep's clothing, a short in disguise....